The Monoclonal Antibody Therapeutics Market, estimated at USD 293.92 Bn in 2025, is expected to exhibit a CAGR of 12.69% and reach USD 678.31 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key market players in the market are focusing on the adoption of organic growth strategies, such as product launches to expand their product portfolio, which is expected to drive market growth over the forecast period. For instance, in February 2025, Eli Lilly and Company, a company engaged in the discovery, development, and marketing of human healthcare products, announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant for the treatment of mild-to-moderate COVID-19.
Global Monoclonal Antibody Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
The COVID-19 had a positive impact on the global monoclonal antibody therapeutics market. For instance, in January 2025, GSK plc, a healthcare company and Vir Biotechnology, a commercial-stage immunology company announced that the U.S. Government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.
Global Monoclonal Antibody Therapeutics Market: Key Developments
Increasing launch of monoclonal antibody therapeutics for the treatment of various autoimmune and infectious diseases is expected to aid in the growth of the global monoclonal antibody therapeutics market in the forecast period
For instance, in September 2025, Gilead Sciences, Inc., a research-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome (MDS).
In February 2025, F. Hoffmann-La Roche Ltd, a biotechnology company that develops drugs and diagnostics to treat major diseases, announced that the World Health Organization (WHO) has granted prequalification to its intravenous (IV) dose of Actemra/RoActemra (tocilizumab) to treat severe or critical COVID-19 patients.
In February 2025, the U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra, announced the purchase of 600,000 treatment courses of a new monoclonal antibody treatment that data shows works against the Omicron variant by the federal government.